Showing results (241-250 of 270) with videos related to
Sort By:
Pageof 27
JTO Clinical and Research Reports|February 15, 2024
Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic TargetsBingnan Zhang, Whitney Lewis, C Allison Stewart, et al.Cancers|December 11, 2025
MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung CancerHui Li, Lingzhi Hong, Pedro Rocha, et al.Therapeutic Advances in Medical Oncology|June 28, 2021
Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access programOliver Illini, Maximilian Johannes Hochmair, Hannah Fabikan, et al.Research Square|May 27, 2024
The evolution of lung adenocarcinoma precursors is associated with chromosomal instability and transition from innate to adaptive immune response/evasionXin Hu, Bo Zhu, Natalie Vokes, et al.Nature Communications|February 8, 2023
Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancerLingzhi Hong, Muhammad Aminu, Shenduo Li, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 3, 2021
Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic TargetXiuning Le, Marcelo V Negrao, Alexandre Reuben, et al.Nature Communications|April 11, 2024
Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insightsSheeba J Sujit, Muhammad Aminu, Tatiana V Karpinets, et al.Nature Communications|July 24, 2025
Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLCMaliazurina B Saad, Qasem Al-Tashi, Lingzhi Hong, et al.The Lancet. Oncology|August 1, 2024
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trialYi-Long Wu, Valentina Guarneri, Pei Jye Voon, et al.Journal for Immunotherapy of Cancer|August 11, 2021
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancerMarcelo V Negrao, Ferdinandos Skoulidis, Meagan Montesion, et al.Pageof 27